Shares of RemeGen Co., Ltd. (OTCMKTS:REGMF – Get Free Report) shot up 28.5% during trading on Thursday . The company traded as high as $12.85 and last traded at $12.85. 4,000 shares changed hands during mid-day trading, an increase of 300% from the average session volume of 1,000 shares. The stock had previously closed at $10.00.
RemeGen Price Performance
The business’s fifty day simple moving average is $10.62 and its 200 day simple moving average is $10.50.
RemeGen Company Profile
RemeGen Co, Ltd. is a Shanghai-based biopharmaceutical company focused on the research, development and commercialization of innovative antibody-based therapeutics for oncology and immunology. Since its founding in 2009, RemeGen has built a portfolio of antibody–drug conjugates (ADCs), monoclonal antibodies and bispecific antibodies aimed at addressing a range of solid tumors and immune-related conditions. The company leverages its in-house discovery, engineering and manufacturing capabilities to advance its pipeline from preclinical stages through clinical trials.
RemeGen’s lead product candidate, Disitamab Vedotin (RC48), is a HER2-targeting ADC that has received regulatory approval in China for HER2-positive gastric cancer and urothelial carcinoma.
Featured Stories
Receive News & Ratings for RemeGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RemeGen and related companies with MarketBeat.com's FREE daily email newsletter.
